VERA
Vera Therapeutics, Inc.
September 15, 2026 · pre-market
- Rarity
- 2.08
- Peak move
- +18.32%
- Float cap
- $2.0B
Vera Therapeutics, Inc. is a late clinical-stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate, atacicept, is being evaluated for immunoglobulin A nephropathy and other autoimmune kidney diseases and is designed for subcutaneous at-home self-administration. It has no products approved for commercial sale.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
10 events · 2 from SEC or newswire · 1 timed with the move- Key eventTimed with the move
clinical_readoutVera Therapeutics reported that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the Phase 3 ORIGIN 3 trial in 428 adults with primary IgA nephropathy, showing 11 vs 38 composite kidney progression events (76% risk reduction) and annual eGFR decline of 0.6 vs 5.6 mL/min/1.73m2 through 104 weeks.
SEC8-K 0001193125-26-391280Webus.kabutan.jpWebcentralcharts.comWebmarketwatch.comWebrttnews.comWebsec.gov peer_disclosureRichard Lafayette, principal investigator for ORIGIN 3, said the final analysis marks a milestone in IgAN treatment, citing reduced kidney disease progression, stabilized eGFR and a favorable safety profile through two years.
- Key event
operating_metricsVera Therapeutics reported over 350 patient start forms for TRUTAKNA in the first ten weeks of US commercial launch, with paid claims being recorded and initial payer policies in place; Chief Commercial Officer Matt Skelton cited the figures ahead of a planned supplemental BLA submission in Q4 2026.
- Key event
clinical_readoutVera Therapeutics said TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the Phase 3 ORIGIN 3 trial in adults with primary IgA nephropathy; CEO Marshall Fordyce said a supplemental BLA targeting full approval will be submitted in Q4 2026, with potential full approval in 2027.
insider_saleVera Therapeutics SVP, Finance and Chief Accounting Officer Joseph R. Young exercised options on 10,000 shares at $3.94 on September 11, 2026.
SEC4 0001861684-26-000006analyst_ratingMarketBeat reported Vera Therapeutics carries a "Moderate Buy" consensus rating from 14 covering firms with an average 12-month price target of $80.15.
insider_saleVera Therapeutics insiders sold 83,250 shares worth about $3.31 million over three months, including CEO Marshall Fordyce's sale of 46,250 shares at an average $42.30 on July 7, 2026.
investor_dayAt the Cantor Fitzgerald Global Healthcare Conference on Sept 10, 2026, Vera Therapeutics management gave a commercial update on TRUTAKNA (atacicept-vymj), including $425,000 annual price, no meaningful payer pushback in 10 weeks, an 82-person sales force, and FDA alignment on an earlier ORIGIN 3 final efficacy analysis.
analyst_ratingJPMorgan raised its price target on Vera Therapeutics to $83 from $76 and kept an Overweight rating on the shares, updating its model ahead of the ORIGIN 3 final analysis.
reg_fd_disclosureVera Therapeutics said its management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 5:35pm ET, with a webcast replay available for 90 days.